Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer

Yonsei University39 enrolled

Overview

The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

Conditions

Biliary Tract Cancer

Interventions

Irinotecan and GemcitabineDRUG

Eligibility

Sex: ALLMin age: 17 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed inoperable biliary tract cancer * Age: 18 \~75 years old * Performance status: ECOG 0-2 * Hematopoietic: * Granulocyte count at least 1,500/mm3 * Platelet count at least 100,000/mm3 * Hepatic: * Bilirubin No greater than 2 fold the upper normal limit * AST/ALT : No greater than 3 fold the upper normal limit * Renal: * Creatinine - no greater than 1.5 mg/dL * Not pregnant * No other serious medical or psychiatric illness that would preclude giving informed consent or limit * No prior chemotherapy within 6 months * No other concurrent anticancer radiotherapy within 6 months

Locations (1)

Severance hospital

Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.